EGFR and lung adenocarcinoma: This is the first known report of a patient with advanced NSCLC, advanced non-smoking lung adenocarcinoma, and no EGFR mutation who survived for nearly 12 years by comprehensive treatment based on EGFR-TKI-based therapy.